- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05673967
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
A Study to Characterize Treatment Patterns and Real-World Outcomes in Heavily Pretreated Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Similar Clinical Characteristics to Patients in the Phase 2 Cohort 2 of the R5458-ONC-1826 Trial
Primary Objective:
1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after meeting the following criteria: (1) have either (a) at least three prior lines (3L) and are triple-class exposed (TCE), or (b) are triple-class refractory (TCR), and (2) meet similar inclusion/exclusion criteria to patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial.
Secondary Objectives:
- To describe additional outcomes (duration of response [DOR], progression-free survival [PFS], overall survival [OS], and time to next treatment [TTNT]) in the same Benchmark Cohort population described in the primary objective.
- To describe distribution of treatment regimens, ORR, DOR, PFS, OS, and to compare ORR, PFS, OS, and TTNT in an Analysis Cohort consisting of real-world patients derived from the Benchmark Cohort described above who are weighted to align with the characteristics of patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial. Comparative analyses of PFS and OS will be performed conditional on sufficient maturity of survival data in the R5458-ONC-1826 (NCT03761108) trial at the time of analysis.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
Tarrytown, New York, United States, 10591
- Regeneron Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1 at baseline
- Confirmed diagnosis of active MM by IMWG diagnostic criteria
- Have myeloma that is response-evaluable with measurable disease by M-protein in serum or urine as specified in the IMWG response criteria.
- Triple-class exposed or refractory
Exclusion Criteria:
- Diagnosis of plasma cell leukemia, primary systemic light-chain amyloidosis (excluding myeloma-associated amyloidosis), Waldenström macroglobulinemia, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin (POEMS) changes syndrome
- Known MM brain lesions or meningeal involvement
- History of neurodegenerative condition, central nervous system (CNS) movement disorder, or seizure
- Cardiac ejection fraction <40% by echocardiogram or multi-gated acquisition scan (MUGA) (or a diagnosis of congestive heart failure, cardiomyopathy, or valvular heart disease as a potential proxy)
- Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent
- Live or live attenuated vaccines
- Treated with B-cell maturation antigen (BCMA)-directed immunotherapies (BCMA antibody-drug conjugates are not excluded).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort 1
Real-world (RW) patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR), meet similar inclusion/exclusion criteria used to establish phase 2 cohort 2 of the R5458-ONC-1826 trial, and are initiating currently available therapies.
|
No study treatment will be administered on this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients exposed to each type of regimen by line of therapy (LOT)
Time Frame: Up to 6 years
|
Distribution of treatment regimens
|
Up to 6 years
|
Proportion of patients with objective response rate (ORR)
Time Frame: Up to 6 years
|
Defined as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR)
|
Up to 6 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR)
Time Frame: Up to 6 years
|
Defined as time from the date of the first documented response (best overall response of sCR, CR, VGPR, PR) until the first date of progressive disease (PD) by International Myeloma Working Group (IMWG) or death due to any cause, whichever occurs first.
|
Up to 6 years
|
Progression-free survival (PFS)
Time Frame: Up to 6 years
|
Defined as time from the start of study treatment until the first date of PD by IMWG, or death due to any cause, whichever occurs first.
|
Up to 6 years
|
Overall survival (OS)
Time Frame: Up to 6 years
|
OS is measured from the start of study treatment until death due to any cause.
|
Up to 6 years
|
Time to next treatment (TTNT)
Time Frame: Up to 6 years
|
Defined as time from the start of study treatment until the initiation of the subsequent LOT.
|
Up to 6 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- R5458-ONC-21101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and Refractory Multiple Myeloma (RRMM)
-
National Cancer Institute (NCI)RecruitingMultiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)United States
-
Janssen-Cilag Ltd.RecruitingRelapsed/Refractory Multiple Myeloma (RRMM)France, Denmark, Israel, Spain, Italy, Germany, Sweden
-
Regeneron PharmaceuticalsRecruitingRelapsed Refractory Multiple Myeloma (RRMM)Canada, United States, Korea, Republic of, Israel, Spain, Australia, Brazil, United Kingdom, Poland, Taiwan, Singapore, France, Italy
-
TakedaTerminatedRelapsed and/or Refractory Multiple Myeloma (RRMM)United States, Canada
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
Carl Ola Landgren, MD, PhDBristol-Myers SquibbRecruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
Clinical Trials on Non-Interventional
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Papworth Hospital NHS Foundation TrustInnovate UK; Cystic Fibrosis Trust; US Cystic Fibrosis FoundationRecruitingCystic FibrosisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruiting
-
Regeneron PharmaceuticalsRecruitingHemophilia BUnited States, Germany, United Kingdom, Canada
-
Henri Mondor University HospitalEuropean Society of Intensive Care MedicineRecruitingFournier Gangrene | Necrotizing Soft Tissue Infection | Necrotizing FasciitisFrance
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Respiratory Effectiveness GroupBoehringer IngelheimCompletedChronic Obstructive Pulmonary DiseaseKorea, Republic of, Singapore, Malta, Italy, Slovenia, Spain
-
Eurasian Association of TherapistsCompletedCardiovascular Diseases | Pneumonia | Hypertension | Diabetes | Covid19 | Coronary Heart Disease | Copd | CKD | Overweight and Obesity | SARS-CoV-2 Infection | Cardiac EventRussian Federation